Influenza Update N° 532

Overview

^{Published 25 June 2025 | For reporting Week 24, ending 15 June 2025}

Influenza

• Globally, influenza activity continued to decrease and was low with influenza A viruses predominant and A(H1N1)pdm09 viruses predominant among the subtyped influenza A viruses.
• In the Southern hemisphere, influenza activity continued to increase, and was moderate to high in a few countries of Temperate South America. Influenza positivity was elevated in countries of Tropical and Temperate South America, Eastern and Southern Africa, South-East Asia and Oceania.
• In the Northern hemisphere, influenza activity remained stable or continued to decline in most countries with increases reported from a few countries in Central America and the Caribbean. Influenza positivity remained elevated in Central America and the Caribbean, Tropical South America, Northern and Western Africa and Western, Southern and South-East Asia.
• Influenza A(H1N1)pdm09 predominated in the America and Oceania. Influenza A(H3N2) was the predominated in Southern Africa and Western, Eastern and South-East Asia. Influenza A(H1N1)pdm09 and A(H3N2) co-circulated in Eastern Africa and Southern Asia.

 

SARS-CoV-2

• Globally, SARS-CoV-2 positivity remained stable and low across the majority of reporting countries. Positivity was elevated (>10%) in a few countries in Central America and the Caribbean, Tropical South America, Northern and South-West Europe and in Western, Southern and South-East Asia, with small increases in activity reported in some countries.

 

Respiratory Syncytial Virus (RSV)

• Globally, SARS-CoV-2 positivity remained stable and low across the majority of reporting countries. Positivity was elevated (>10%) in a few countries in Central America and the Caribbean, Tropical South America, Northern and South-West Europe and in Western, Southern and South-East Asia, with small increases in activity reported in some countries.

WHO encourages countries, especially those that have received the multiplex influenza and SARS-CoV-2 reagent kits from GISRS, to conduct integrated surveillance of influenza and SARS-CoV-2 and report epidemiological and laboratory information in a timely manner to established regional and global platforms. The guidance can be found here https://www.who.int/publications/i/item/WHO-2019-nCoV-integrated_sentinel_surveillance-2022.1.
 

Starting with report #501, the Global Respiratory Virus Activity Weekly Update included data from sentinel surveillance and other types of systematically conducted virologic surveillance. Countries, areas, and territories use a variety of approaches to monitor respiratory virus activity and data in this report may vary from surveillance reports posted elsewhere. Analyses stratified by source of surveillance is available through Respimart.